|
| Formoterol fumarate dihydrate Basic information |
Product Name: | Formoterol fumarate dihydrate | Synonyms: | Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, rel-, (2E)-2-butenedioate (2:1) (salt), dihydrate;Unii-W34shf8J2k;(±)-(R,R)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamidehemifumarate;Formoterol fumarate dihydrate ,98.5%;(r*,r*)-n-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide fumarate dihydrate;Formoterol Fumarate (100 mg);forMaMide fuMarate dihydrate;N-(2-hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-Methoxyphenyl)propan-2-yl)aMino)ethyl)phenyl)forMaMide fuMarate dihydrate | CAS: | 183814-30-4 | MF: | C23H28N2O8 | MW: | 460.48 | EINECS: | | Product Categories: | Other APIs;API;Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals | Mol File: | 183814-30-4.mol | |
| Formoterol fumarate dihydrate Chemical Properties |
Melting point | 116-120°C | storage temp. | 2-8°C | solubility | DMSO: soluble20mg/mL | form | solid | color | white to off-white | InChIKey | RATSWNOMCHFQGJ-XODSYJLDSA-N | SMILES | C(/C(=O)O)=C\C(=O)O.[C@@H](C1C=CC(O)=C(NC=O)C=1)(O)CN[C@@H](C)CC1C=CC(OC)=CC=1 |&1:8,22,r| | CAS DataBase Reference | 183814-30-4 |
RIDADR | UN 2811 6.1 / PGII | WGK Germany | 3 | HS Code | 29242990 |
| Formoterol fumarate dihydrate Usage And Synthesis |
Chemical Properties | Pale Yellow Solid | Uses | Formoterol is a selective β2-adrenergic receptor agonist. Formoterol is used as an antiasthmatic. | Uses | ForMoterol FuMarate Dihydrate is a selective β2-adrenergic receptor agonist,it is used as an antiasthmatic. | Biological Activity | Potent, selective and long-acting β 2 -adrenoceptor agonist. Displays 330-fold selectivity for β 2 over β 1 receptors (pK d values are 8.12 and 5.58 respectively). Potently relaxes guinea pig trachea (pD 2 = 9.29), and is longer-acting and 100-fold more potent than salbutamol. | Biochem/physiol Actions | β2-Adrenoreceptor agonist. | Drug interactions | The efficacy and tolerability of glycopyrronium/formoterol fumarate metered dose inhaler, a fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) delivered by metered dose inhaler using innovative co-suspension delivery technology, was investigated in patients (n = 292) with COPD [12C]. There were no meaningful pharmacokinetic interactions, whether drug–drug or due to formulation, between glycopyrronium and formoterol following treatment with formulated using a new co-suspension delivery technology. The incidence of cardiovascular events of special interest was low (stroke, 0%–0.4%; cardiac ischemia, 0.4%–2.3%; cardiac failure, 1.3%–2.5%; arrhythmia, 1.3%–3.2%), and no important trends in clinical laboratory results, vital signs, or electrocardiograms were observed[1].
| References | [1] Aagaard, Lise . "A worldwide yearly survey of new data in adverse drug reactions." (2014). |
| Formoterol fumarate dihydrate Preparation Products And Raw materials |
|